China’s biotech sector is staging a strong comeback in 2025, driven by a surge in licensing deals, improving fundamentals, and revived investor interest, even as U.S. biotech struggles with political headwinds and regulatory setbacks. Data from DealForma shows Chinese companies now account for 42% of $50M+ licensing deals, highlighting China’s growing role in global biopharma innovation. Read the article here
